FIGO stage IIIB and IIIC ovarian epithelial tumor
Conditions
Interventions
Group 2:abdominal primary cytoreduction
Sponsors
Obstetrics and Gynecology of the First Affiliated Hospital of Army Medical University, PLA
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. definitely diagnosing the ovarian epithelial cancer before or during surgery by biopsy; 2. female aged between 18-70 years old; 3. tumors confined to abdominopelvic cavity,preoperatively evaluated or laparoscopic explore as the FIGO IIIB and IIIC; 4. the largest tumor diameter =15cm; 5. without any medical and surgical complications and laparoscopic surgey'contraindications; 6. patients volunteer to join in the study and follow up; 7. Fagotti score=8; 8. patients who received six to eight cycles of platinum-based chemotherapy and finished twice Intraperitoneal chemotherapy.
Exclusion criteria
Exclusion criteria: 1. once receiving abdominal surgery for maglignant tumor or abdominal surgery more than once; 2. large abdominal mass or ascites causing difficult breathing or CO2 pneumoperitoneum; other unexpected occasions elevated by the operator so as to abdominal surgery; 3. complicated with DIE; 4. pregnant women or pregnancy tests(serum or urine) showing positive seven days ago before enrolling; 5. patiens and relations involuntary to the study or unaffordable to study hazards; 6. conforming the laparoscopybased exclusion criteria; 1) massive omental cake; 2) obliterated Morisons pouch; 3) involvement of lesser omentum; 4) involvement of the retrohepatic diaphragm, multiple(>3) and/or single (>2cm) diaphragmatic carcinomatosis; 5) larger than 2cm disease on the surface or/and on the right lobe of liver larger than 2cm or/and involvement of liver parenchyma or/and; 6) unresectable upper abdominal metastases such as omental disease involving the spleen; 7) the necessity of more than two bowel resections; 8) bulky aortic nodal; 9) obliterated spleno-colic ligament.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survial;disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| residual tumor; | — |
Countries
China
Contacts
Public ContactZhiqing Ling
Obstetrics and Gynecology of the First Affiliated Hospital of Army Medical University, PLA
Outcome results
None listed